Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HTM each quarter always goes in 'hibernation' after e's. Flippers will loose intrest and leave. Look for another run up closer to next quarterly results.
Good morning ~ HTM what? no growth prospects?? what will the canacrap analyst say now after he downgraded HTM stating he didn't see any growth prospects. What an ass!
HTM I agree keeping a core is what I do while swingtrading opportunities such as run ups into e's.
I am hoping HTM will become my next DYNEGY
Good morning ~ HTM they are executing their recent announced plans. 5 completed wells available for immediate production with roughly 30 megawatts of total steam behind pipe, infrastructure is in place, the acquisition will be funded with cash on hand, that is great news!
Also Gilles background is with Calpine in the Geysers steam fields so he definitaly knows what he is doing.
"We had previously announced that our plan for continued growth would come through a combination of the development of internal projects and growth thru strategic acquisition. This acquisition at the Geysers is a solid first step in the execution of that plan."
Hi h, CBLI there is not much to tell other than the poster presentation, new cash input and the technical aspect there is nothing life changing.
My apologies for the late reply I wasn't online the last few days... My twin daughters were scheduled for an elective surgery but one of the girls was afterwards put in an artificial coma and was lifted out of it yesterday morning. I stayed all night by their side on IC. They both are ok now.
CBLI added
RGDX wild... took my profit
CBLI now 0.83 in PM
Running ahead of the poster presentation this Sunday in S. Diego
RGDX announces contracts with six new provider networks, bringing the total contracted membership to more than 174 mln members nationally
The new agreements include additional Blue Cross Blue Shield contracts in Arizona, Iowa, South Dakota, Pennsylvania, Delaware, and West Virginia. The Company also signed new agreements with an Independent Physician Association (covering two states) in the North West region and a Commercial Health Plan (covering two states) in the North East region of the United States.
These partnerships mark a further step forward in Response Genetics' growing managed care contracting program. With these agreements, Response Genetics is now in-network with a total of thirteen Blue Cross Blue Shield health plans, which brings the total number of "Blues" subscribers with direct access to Response Genetics to approximately 23 million. Among Response Genetics' other Blue Cross Blue Shield contracts are Blue Cross and Blue Shield of Illinois, Blue Shield of California and CareFirst BlueCross BlueShield (Maryland, Washington, DC and Northern Virginia).
In addition to its recently launched proprietary ResponseDX: Tissue of Origin™ diagnostic test, Response Genetics' molecular testing primarily focuses on therapy-selection for patients with lung, colon, gastric, melanoma, and thyroid cancers. Response Genetics' menu of genomic assays provides treating physicians actionable information on a patient's tumor by predicting which course of therapy will work best for that patient. In this way, Response Genetics' participation with these Blues plans should improve plan members' access to individually-tailored medicine.
CBLI 0.80 in AH
CBLI let's go! Lets close that gap
HTM I agree. The turn around of this clean, renewable, evironmentally friendly utility company should be put more often in the spotlights.
It is time we should more and more step away from fossil fuel.
We should start talking about the stock, the company and the business growth imo.
HTM We should get some buyers today because of this article.
HTM has been in recent times moved from being a traditional energy player with conservative green policies, into becoming a proactive utility business, which is able to meet market demands, where necessary.
HTM has seen growth due to multiple-phases of growth an asset performance. In th erecent times it has also concertrated on working with fundementally stronger partners.
http://www.financialstrend.com/u-s-geothermal-inc-nysemkthtm-posts-great-value-16539.html
CBLI CBL0137 Combination Studies to Be Presented at 2014 AACR Annual Meeting 5 - 6 April
Intravenous administration of CBL0137 is being evaluated in a Phase 1 trial with patients with metastatic or unresectable advanced solid cancers and lymphomas. Oral administration of CBL0137 is being assessed in a Phase 1 study of patients with advanced solid tumors that are resistant or refractory to current standard treatment. To date, no drug-related serious adverse events have been reported in either trial.
Good morning HTM WASHINGTON, March 28 (Reuters) - The U.S. Energy Department will soon issue a plan to offer loan aid for renewable energy projects, Energy Secretary Ernest Moniz said on Friday, doubling down on investments that have drawn intense criticism over past government-backed business flops.
This includes Geothermal Plants on a utility scale.
Upto $8 Billion maybe available on a low interest Government backed loan scheme.
This could be good news for HTM. In the past HTM did receive a loan from the government.
Good morning h, i am currently looking at a few biotech stocks that got bruised lately. MSTX, RGDX (below offering at 1.20), KIPS (also fell below offering at 0.70). Ready to take positions.
Still holding CBLI, HTM
And this Belgian company
MDxHealth Licensee Exact Sciences Receives FDA Panel Recommendation for Approval of Colorectal Cancer Screening Test
MDxHealth's Epigenetic Biomarker Used in Cologuard Test
IRVINE, CA, and HERSTAL, BELGIUM - March 28, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the Molecular and Clinical Genetics Panel of the United States Food and Drug Administration's (FDA) Medical Devices Advisory Committee strongly endorsed approval of Cologuard(TM). The Committee determined by a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard, the company's stool-based DNA (sDNA), non-invasive colorectal cancer screening test. Cologuard incorporates one of MDxHealth's epigenetic biomarkers and methylation specific PCR (MSP) technology, which was licensed to Exact Sciences in July 2010.
"Colorectal cancer is the second leading cause of cancer death in the United States yet often viewed as the most preventable," stated Dr. Jan Groen, CEO of MDxHealth. "We are very proud to see that one of our epigenetic biomarkers is a key component of the biomarker panel incorporated in the Cologuard screening test."
Cologuard is designed to detect specific changes in a patient's DNA that appear in the stool, which could indicate the presence of colorectal cancer or pre-cancerous polyps. The test also identifies the presence of blood in the stool, another indicator of possible colorectal cancer.
"We are pleased the Committee strongly supported Cologuard's approval," said Kevin T. Conroy, chairman and chief executive of Exact Sciences. "We look forward to continuing our work with the FDA to complete its review of Cologuard and remain committed to addressing the growing unmet needs in colorectal cancer screening. We thank the FDA and its advisory committee for its careful consideration of Cologuard. We also appreciate the opportunity to participate in the innovative FDA/CMS parallel review program."
Cologuard is an investigational device currently under review by the U.S. Food and Drug Administration (FDA) and is not available for sale in the United States. The Committee's recommendation will be taken into consideration by the FDA in its final review of the Cologuard test. The FDA is not bound by the Committee's guidance but often follows this expert guidance.
About MDxHealth
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, ConfirmMDx® for Prostate Cancer, has been validated to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer, thereby aiding in the reduction of unnecessary repeat biopsies. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain, bladder and lung cancers. For more information visit www.mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
Good morning h, i am currently looking at a few biotech stocks that got bruised lately. MSTX, RGDX (below offering at 1.20), KIPS (also fell below offering at 0.70). Ready to take positions.
Still holding CBLI, HTM
And this Belgian company
MDxHealth Licensee Exact Sciences Receives FDA Panel Recommendation for Approval of Colorectal Cancer Screening Test
MDxHealth's Epigenetic Biomarker Used in Cologuard Test
IRVINE, CA, and HERSTAL, BELGIUM - March 28, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the Molecular and Clinical Genetics Panel of the United States Food and Drug Administration's (FDA) Medical Devices Advisory Committee strongly endorsed approval of Cologuard(TM). The Committee determined by a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard, the company's stool-based DNA (sDNA), non-invasive colorectal cancer screening test. Cologuard incorporates one of MDxHealth's epigenetic biomarkers and methylation specific PCR (MSP) technology, which was licensed to Exact Sciences in July 2010.
"Colorectal cancer is the second leading cause of cancer death in the United States yet often viewed as the most preventable," stated Dr. Jan Groen, CEO of MDxHealth. "We are very proud to see that one of our epigenetic biomarkers is a key component of the biomarker panel incorporated in the Cologuard screening test."
Cologuard is designed to detect specific changes in a patient's DNA that appear in the stool, which could indicate the presence of colorectal cancer or pre-cancerous polyps. The test also identifies the presence of blood in the stool, another indicator of possible colorectal cancer.
"We are pleased the Committee strongly supported Cologuard's approval," said Kevin T. Conroy, chairman and chief executive of Exact Sciences. "We look forward to continuing our work with the FDA to complete its review of Cologuard and remain committed to addressing the growing unmet needs in colorectal cancer screening. We thank the FDA and its advisory committee for its careful consideration of Cologuard. We also appreciate the opportunity to participate in the innovative FDA/CMS parallel review program."
Cologuard is an investigational device currently under review by the U.S. Food and Drug Administration (FDA) and is not available for sale in the United States. The Committee's recommendation will be taken into consideration by the FDA in its final review of the Cologuard test. The FDA is not bound by the Committee's guidance but often follows this expert guidance.
About MDxHealth
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, ConfirmMDx® for Prostate Cancer, has been validated to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer, thereby aiding in the reduction of unnecessary repeat biopsies. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain, bladder and lung cancers. For more information visit www.mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
IGC tough one but she has her moments
Oh Vegas nice! I was there in July for 3 weeks. Have fun!
LOL stay away from profitable companies!!!!
Thank you for 'marking' me My apologies for not responding sooner, I hadn't noticed it. I suppose I am not used to receiving marks, regardless I appreciate it. May I perhaps also know why?
Cheers
ps: mind you I have limited posts, so if I don't respond back you know why
MSTX in the excitement of y'day totally forgot to mention this news as stated in my previous mssg.
Should bounce back from here.
Mast Therapeutics Initiates Phase 2 Study Of MST-188 In Patients With Acute Limb Ischemia
- Study will evaluate whether MST-188 improves the effectiveness of rt-PA
- Represents second clinical-stage program for MST-188
- Potential application in other settings in which rt-PA is used
HTM gm, criminal what happened yesterday. No other words for it. But thank you for sharing.
HTM yes, one of their guys (Doug) is having a discussion with the power broker with whom they have an MOU with. This is what they said.
I ran out of free posts for today so this is my last.
Cheers!
HTM they have a power broker too down there
HTM plans and permits are signed already which is really big.
HTM you're welcome. I can also add that there was an 118% increase in Q4 compared to Q3. Also that drilling in Guatemala exceeded expected temperatures and that they are now doing further survey and testing which takes a few more weeks.
Enbridge (40% partner in Neal Hot Springs) has definitely expressed a strong interest in participating with them in future projects but Enbridge is only interested in investing in the US and Canada.
Swing it and hold your core cause this is going up up up !
Aaaaawwww is that so
HTM it is called stupidity, profit taking and clueless behaviour. I hate that! LOL
HTM quick update:
* 2014 plant availability 90% throughout 2014
* projecting normal weather as opposed to abnormally hot weather in 2013
* Guatemala MOE on the table - plans and permits signed to drill up to 4 wells
* development San Emilio going great expecting further news end of Q1 or Q2
* lookng for strategic acquisitions
* pre-emptive PR about lease acquisition (stayed mysterious around it)
* No nearby plans to raise equity at this point in time
HTM managment is in Guatemala (wow!!!!), call has started
HTM is the call starting in 3 min or am I one hour too early?
Don't think we're going to need an umbrella...
Partly cloudy (ugh!) partly sunny (love!). We did not have one single snow flake this year here in Belgium and I am quiet happy with that.
HTM let's keep her steady going into the call but expect some turbulance. If you want to see the sunshine, you'll have to storm the weather;
Nice to hear you say that
HTM guidance for 2014
2014 Full Year Guidance (in millions):
2014
Operating Revenue $27 - 31
EBITDA $13 - 16
Net Income $2.5 - 5.5
performance for 2013 exceeded our expectations, with Generation, Revenues, EBITDA, and Net Income all exceeding the high end of the guidance that we had previously provided for calendar year 2013
Wrapping up the year with an especially strong fourth quarter performance allowed us to not only meet, but beat, the guidance we had previously provided.
HTM so nice to see how many held through earnings against all rules. You never do wrong taking profits but when the fundamentals are there as is the case here with HTM, you sometimes have to follow common sense to see where this is going.
The results were even better than expected and it can only get better from here, slowly yes definitely but surely.
Can't wait to read the headlines today! And where this is going.
Good luck everyone! Cheers!
HTM I am *impressed* - few numbers
4Q operating rev $9.550.373
Gross profit $5.635.824
Operating rev $27.370.934 vs $9.758.946 in 2012
Cash $28.736.934 vs $12.908.779 in 2012
HTM good luck holders